Case Report

Myelodysplastic Syndrome Clinically Presenting with the “Classic TTP Pentad”

Santiago Fabián Moscoso Martínez,1 Evelyn Carolina Polanco Jácome,2 Elizabeth Guevara,1 and Vijay Mattoo1

1Department of Hematology and Oncology, The Brooklyn Hospital Center, 121 Dekalb Ave, New York, NY 11201, USA
2Department of Pathology, Hofstra Northwell Health School of Medicine, 6 Ohio Drive, New Hyde Park, NY 11042, USA

Correspondence should be addressed to Santiago Fabián Moscoso Martínez; sanmoscoso@gmail.com

Received 26 August 2016; Revised 6 January 2017; Accepted 16 January 2017; Published 1 February 2017

Academic Editor: Sergio Storti

Copyright © 2017 Santiago Fabián Moscoso Martínez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The clinical presentation of myelodysplastic syndrome (MDS) is not specific. Many patients can be asymptomatic and can be detected only due to an abnormal complete blood cell count (CBC) on routine exam or for other reasons while others can be symptomatic as a consequence of underlying cytopenias. Thrombotic thrombocytopenic purpura (TTP) usually is suspected under the evidence of microangiopathic hemolytic anemia (MAHA) and thrombocytopenia and because it is a life-threatening condition (medical emergency) immediate initiation of plasmapheresis could be life-saving. The following case illustrates an unusual presentation of MDS in a patient who came in to the emergency room with the classic TTP “pentad” of fever, renal involvement, MAHA, mental status changes, and thrombocytopenia. We will focus our discussion in the clinical presentation of this case.

1. Introduction

MDS is a clonal stem-cell disorder characterized by dyshematopoiesis and dysplasia of single or multiple blood cell lines causing progressive cytopenias. As a result, MDS, if symptomatic, is manifested with signs and symptoms related to the severity of the underlying cytopenias (e.g., fever, infection, pallor, fatigue, petechiae, ecchymosis, bleeding, and hematomas). However, MDS in an elderly patient presenting as full-blown TTP is unusual. We present a case of a sixty-six-year-old woman coming to the emergency room with the classic TTP “pentad” and ended up with a diagnosis of MDS.

2. Case Report

A 66-year-old African American female without significant personal or family medical history and who has not been followed by any physician for years came in to the emergency department due to acute onset altered mental status changes. As per patient’s daughter, she was in good health until the night prior to admission after a two-mile walk. In the morning she was noticed to be drowsy and confused “trying to drink her hair as if it were a glass of water”. She could not identify her daughter and she was complaining of generalized weakness as well as right groin pain. As the morning went by she was progressively getting worse becoming somnolent and stopped responding to verbal commands. She was brought to the emergency room where she was found to be febrile (as high as 106 degrees Fahrenheit), tachycardic (145 beats per minute), and tachypneic (25 breaths per minute) with a normal blood pressure. She was only responsive to painful stimuli with no meningeal signs. No palpable organomegaly or cervical, supraclavicular, axillary, or inguinal lymphadenopathy was found.

Complete blood cell count showed normocytic anemia (Hb 6.6 g/dL; MCV 91), thrombocytopenia (platelet count 77,000), and slight leukocytosis with neutrophilia (WBC 13,400. ANC 11,800). Further testing revealed an elevated LDH 1248 U/L (125–220 U/L), reticulocyte count 3.5% (1-2%), mild indirect hyperbilirubinemia (total bilirubin 1.4 mg/dL and direct bilirubin 0.3 mg/dL), and mildly elevated creatinine (1.2 mg/dL). Vitamin B12 level, folate level, prothrombin time, partial thromboplastin time, and INR were all normal as well as fibrinogen level (402 mg/dL). Serum iron was 6
mcg/dL (50–170 mcg/dL), total iron binding capacity was 257 mcg/dL (179–378 mcg/dL), and ferritin was 378 ng/mL (10–204 ng/mL). Urinalysis showed microscopic hematuria and proteinuria (30 mg/dL). Antibodies to human immunodeficiency virus were negative. Peripheral smear showed marked schistocytosis (Figure 1) and dysplastic neutrophils (Figures 2(a) and 2(b)).

Chest X-ray and computed tomography (CT) of the head were unremarkable. Because of the compelling evidence of microangiopathic hemolytic anemia (MAHA) associated with thrombocytopenia, altered mental status, fever, and renal involvement thrombotic thrombocytopenic purpura (TTP) was strongly considered. ADAMTS-13 was sent and she was started on daily plasmapheresis and steroids. Platelet count dropped even further in the next couple of days (nadir 9,000) and there was no improvement in the MAHA (including the persistent marked schistocytosis) Table 1. ESR was 5 (normal range: 0–20 MM/HR). Three days after the beginning of plasmapheresis the test results for haptoglobin as well as for ADAMTS-13 activity came back and they were 120 (14–250 mg/dL) and 52% (normal: 68–163%), respectively. Plasmapheresis was stopped. Urine culture and blood cultures were negative for infection. CT chest, abdomen, and pelvis with contrast as well as CT angiogram of the lower extremities were unremarkable. Flow cytometry showed no evidence of B-cell lymphoma, T-cell lymphoma, acute leukemia, or increase in blasts.

She underwent to bone marrow aspiration and biopsy which showed markedly hypercellular marrow, hyperplastic and dysplastic megakaryocytic, and dyspoietic erythroid elements with occasional binucleate forms and irregular contour, and myeloid elements showed slight left shift. There was mild increase in reticulin fiber content making a myelophthisic process as the underlying cause of schistocytosis unlikely (Figures 3–7). There was no evidence of plasma cell disorder. Iron stain on biopsy showed mild increase in stainable iron (3+) and no ring sideroblasts. There was no increase in blasts.

Karyotype analysis in twenty metaphases was performed and revealed a complex karyotype in eight metaphases (Figures 8 and 9). Twelve metaphases were chromosomally normal. Due to all these findings the final diagnosis was MDS with multilineage dysplasia [1] and she was referred for a clinical trial.

3. Discussion

This is a case of an elderly patient with MDS clinically presenting with the “classic TTP pentad.” To the best of the authors’ knowledge this is the first case reported of MDS presenting as full-blown TTP in an elderly person. There are three cases in the twenties reporting the association between TTP and MDS [2–4]. Our case illustrates that MDS can
Table 1: Schematic representation of hemoglobin, platelets, schistocytes, and plasmapheresis.

|                  | Day 1 | Day 2 | Day 3                  | Day 4 |
|------------------|-------|-------|------------------------|-------|
| Hemoglobin (g/dL)| 6.6   | 6.8   | 7.7 (transfused one unit) | 7.0   |
| Platelets (K/cmm)| 77    | 50    | 12                     | 9     |
| Schistocytes     | Marked| Marked| Marked                 | Marked|
| Plasmapheresis   | Started| Continued| Continued               | Stopped|

Figure 3: Bone Marrow Core Biopsy: low power magnification, highly cellular bone marrow.

(a) (b)

Figure 4: Bone Marrow Core Biopsy: picture (intermediate magnification, H&E) shows a hypercellular bone marrow with increased number of dysplastic megakaryocytes. Dysplastic features include nuclear hypolobation (a) and micromegakaryocytes (b).

Figure 5: Bone marrow aspirate smear: dysplastic megakaryocytes, 100x magnification multinucleated megakaryocyte.
Figure 6: Bone marrow aspirate smear: dysplastic megakaryocyte, 100x magnification megakaryocyte with nuclear hypolobation.

Figure 7: Bone marrow aspirate shows dyserythropoiesis including megaloblastic change (A) and nuclear budding (B).

Figure 8: Bone marrow specimen showing 48,XX,+1,+14,t(14;22)(q32;q11.2),add(15)(q22),+16,add(16)(q12-13),add(17)(p11.2),−22,inc.
Clinically present as TTP and life-saving treatment such that plasmapheresis in this acute clinical setting should not be delayed until further testing to clarify the diagnosis is in process.

MDS generally affects older adults (median age 76 years) [5]. Clinically MDS can be incidentally found in a work-up done for other reasons (CBC showing anemia, leukopenia, or thrombocytopenia) and being asymptomatic usually in half of the cases [6] or it can be symptomatic with clinical features related to the severity of the underlying cytopenias which in turn are due to ineffective hematopoiesis.

At least 80–90% will have anemia at the time of diagnosis; it is usually normocytic or macrocytic, and half of them will have an Hb less than 10 g/dL [7]. Anemia can be manifested as fatigue, generalized weakness, exercise intolerance, angina, dizziness, or altered mental status [8–11]. In the present case her Hb on admission was 6.6 g/dL explaining her fatigue, generalized weakness, and at least in part her altered mental status.

Thrombocytopenia is present in 30–45% of cases and approximately 40% are neutropenic at the time of diagnosis [7]. As a result of them and less often patients can have petechial rash, easy bruising, inappropriate bleeding, hematomas, or infection. Our patient did not have clear evidence of infection by physical exam, cultures, and imaging studies. After approximately a week she was found to have a right thigh abscess that was drained. The cause of fever appears to be due to underlying infection. Weight loss is rare and represents a late manifestation of MDS.

On physical exam there are not specific findings related to MDS. Pallor is seen in 60% of the cases and rash and purpura in 26%. Lymphadenopathy, splenomegaly, and hepatomegaly are uncommon [9, 12].

MDS can be suspected when there is unexplained monocytosis, cytopenias, macrocytosis (even with normal hemoglobin), or cellular atypia and dysplasia. In our case the presence of cytopenias and cellular dysplasia were suggestive of MDS.

Peripheral blood smear findings described in the erythroid line in MDS include spherocytes, macroovalocytes, acanthocytes, elliptocytes, stomatocytes, teardrop cells, nucleated erythrocytes, basophilic stippling, and Howell-Jolly bodies. However, schistocytes have been rarely described and to the best of our knowledge, only 4 cases have been reported in the English language literature [13–15]. In the present case, schistocytosis could be due to an underlying disseminated intravascular coagulation (DIC) perhaps due to an underlying infection (thigh abscess).

The initial presentation of acute onset and rapidly progressive worsening altered mental status changes, fever, anemia with marked schistocytosis (MAHA), thrombocytopenia, and renal involvement made TTP occupy the top in the list of the differential diagnosis in this unusual case.
Diagnosis of MDS relies on the morphological assessment of bone marrow aspiration and biopsy as well as on the cytogenetic analysis. In some occasions bone marrow aspiration and biopsy need to be repeated more than once since MDS can affect the bone marrow unevenly and it can cause false negatives.

4. Conclusion

In an elderly patient who presents with anemia and marked schistocytosis (microangiopathic hemolytic anemia) associated with thrombocytopenia MDS should be considered in the differential diagnosis. As illustrated in the present case, MDS can even present with the classic TTP "pentad" of fever, renal involvement, anemia (MAHA), mental status changes, and low platelets (thrombocytopenia). In this clinical context, MDS becomes a diagnosis of exclusion and life-threatening conditions such that TTP needs to be addressed first with appropriate evaluation and initiation of pertinent treatment until this medical emergency is being ruled out.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] D. A. Arber, A. Orazi, R. Hasserjian et al., “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia,” *Blood*, vol. 127, no. 20, pp. 2391–2405, 2016.
[2] N. Sasaki, J. Kuroda, E. Kawata et al., “Thrombotic thrombocytopenic purpura associated with myelodysplastic syndrome,” *International Journal of Hematology*, vol. 88, no. 4, pp. 457–459, 2008.
[3] I. Doudenko-Pirozzolo and R. Booth, “Pathologic quiz case: a 20-year-old man with a history of hemoptysis and purpura,” *Archives of Pathology and Laboratory Medicine*, vol. 125, no. 6, pp. 835–837, 2001.
[4] G. Leone, S. Sica, V. De Stefano et al., “Acute onset of juvenile myelodysplastic syndrome mimicking thrombotic thrombocytopenic purpura and rapidly evolving in overt myeloid leukemia,” *American Journal of Hematology*, vol. 41, no. 1, pp. 64–65, 1992.
[5] X. Ma, M. Does, A. Raza, and S. T. Mayne, “Myelodysplastic syndromes,” *Cancer*, vol. 109, no. 8, pp. 1536–1542, 2007.
[6] V. Santini, “Anemia as the main manifestation of myelodysplastic syndromes,” *Seminars in Hematology*, vol. 52, no. 4, pp. 348–356, 2015.
[7] D. P. Steensma and J. M. Bennett, “The myelodysplastic syndromes: diagnosis and treatment,” *Mayo Clinic Proceedings*, vol. 81, no. 1, pp. 104–130, 2006.
[8] S. L. Goldberg, E. Chen, M. Corral et al., “Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries,” *Journal of Clinical Oncology*, vol. 28, no. 17, pp. 2847–2852, 2010.
[9] K. Foucar, R. M. Langdon II, J. O. Armitage, D. B. Olson, and T. J. Carroll Jr., “Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases,” *Cancer*, vol. 56, no. 3, pp. 553–561, 1985.
[10] A. J. G. Jansen, M.-L. Essink-Bot, E. A. M. Beckers, W. C. J. Hop, M. R. Schipperus, and D. J. Van Rhenen, “Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes,” *British Journal of Haematology*, vol. 121, no. 2, pp. 270–274, 2003.
[11] C. A. Meyers, M. Albilar, and E. Estey, “Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome,” *Cancer*, vol. 104, no. 4, pp. 788–793, 2005.
[12] H. P. Koeffler and D. W. Golde, “Human preleukemia,” *Annals of Internal Medicine*, vol. 93, no. 2, pp. 347–353, 1980.
[13] J. L. Rummens, C. Verfaillie, A. Criel et al., “Elliptocytosis and schistocytosis in myelodysplasia: report of two cases,” *Acta Haematologica*, vol. 75, no. 3, pp. 174–177, 1986.
[14] M. F. Zahid, N. Khan, J. Pei, J. R. Testa, and E. Dulaimi, “Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia,” *Leukemia Research Reports*, vol. 5, pp. 23–26, 2016.
[15] J. W. Hartz, D. H. Buss, D. R. White, M. G. Bond, and M. Schary, “Marked elliptocytosis and schistocytosis in hematopoietic dysplasia,” *American Journal of Clinical Pathology*, vol. 82, no. 3, pp. 354–359, 1984.